Cagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with no hypoglycemia and lower nausea than GLP-1 drugs, though its real role is the amylin half of CagriSema.
Cagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy over 68 weeks in the Phase 3 REDEFINE 1 trial, per Garvey 2025. The single most important thing to understand is what it is not. It is not a GLP-1 drug. It works on a separate appetite pathway, which is exactly why it sits at a modest score on its own yet becomes far more interesting when combined with semaglutide. If you came here thinking cagrilintide is a cheaper Ozempic, that framing is wrong, and the rest of this report explains why.
These entries name compounds evaluated together in a human study. They are not instructions to combine treatments.
Cagrilintide + semaglutide (CagriSema)
A randomised human trial evaluated this fixed combination against its component therapies. That makes it a co-studied relationship, not a DIY pairing or a recommendation to combine medicines.
CompoundingCannot be used in compounding under US federal law
FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.